▶The U.S. healthcare system contains significant structural inefficiencies, particularly the Pharmacy Benefit Manager (PBM) model that inflates drug list prices and a decentralized, slow clinical trial system that hinders development.May 2026
▶Eli Lilly is making a massive strategic investment in technology, highlighted by the construction of what Dave Ricks believes is the world's largest biologically-focused supercomputer with NVIDIA, intended to run proprietary drug discovery models.May 2026
▶The cost of developing a new drug is exceptionally high, estimated at $3.5 to $4 billion, with over 60% of that cost and significant time delays occurring in late-stage (Phase 3) clinical trials and patient enrollment.May 2026
▶The Inflation Reduction Act (IRA) represents a major policy shift, introducing government price interventions for drugs approximately seven years after their market launch, which impacts the financial modeling for pharmaceutical innovation.
▶Ricks heavily criticizes the PBM model for inflating insulin list prices, yet Eli Lilly participated in this system for years before launching its own lower-priced generic, which then struggled to get formulary coverage, highlighting a complex dynamic of complicity and attempted reform.May 2026
▶He champions the cost-effectiveness of GLP-1s like Zepbound, citing favorable ICER analysis, while also stating that the self-pay option via Lilly Direct is the leading channel for new patients, suggesting a conflict between demonstrated value and practical insurance coverage.
▶Ricks expresses confidence in Eli Lilly's rapid drug development timeline but simultaneously warns that the entire industry is fragile, citing the '10-year chill' from past regulatory actions (Vioxx/Avandia) and new pressures from the IRA.May 2026
▶He advocates for massive, publicly-funded (NIH) biological data generation for AI, yet his own company is investing heavily in a private, on-premise supercomputer for proprietary models, indicating a tension between advancing public science and securing a private competitive edge.
Not enough data for timeline
Sign up free to see the full intelligence report
Get started free